Pregabalin
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Seizures
Conditions
Seizures
Trial Timeline
Nov 1, 2004 → May 1, 2006
NCT ID
NCT00141427About Pregabalin
Pregabalin is a approved stage product being developed by Pfizer for Seizures. The current trial status is completed. This product is registered under clinical trial identifier NCT00141427. Target conditions include Seizures.
What happened to similar drugs?
6 of 20 similar drugs in Seizures were approved
Approved (6) Terminated (2) Active (13)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01773993 | Pre-clinical | Completed |
| NCT01603394 | Approved | Terminated |
| NCT01463306 | Phase 3 | Completed |
| NCT01298466 | Approved | Withdrawn |
| NCT01474772 | Phase 3 | Completed |
| NCT01397006 | Approved | Withdrawn |
| NCT01020526 | Approved | Completed |
| NCT01202227 | Phase 3 | Completed |
| NCT01226667 | Approved | Completed |
| NCT00819988 | Phase 3 | Completed |
| NCT00596466 | Phase 3 | Completed |
| NCT00553280 | Phase 3 | Completed |
| NCT01061697 | Approved | Completed |
| NCT00891397 | Pre-clinical | Terminated |
| NCT00448916 | Phase 3 | Completed |
| NCT00407797 | Approved | Terminated |
| NCT00424372 | Phase 3 | Completed |
| NCT00407511 | Approved | Completed |
| NCT00346034 | Phase 3 | Completed |
| NCT00843284 | Pre-clinical | Completed |
Competing Products
20 competing products in Seizures
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| E2007 | Eisai | Phase 3 | 40 |
| Perampanel | Eisai | Pre-clinical | 26 |
| perampanel + perampanel + perampanel + Placebo | Eisai | Phase 3 | 40 |
| perampanel | Eisai | Phase 2 | 35 |
| Perampanel | Eisai | Pre-clinical | 26 |
| Zonisamide + Placebo | Eisai | Phase 3 | 40 |
| zonisamide | Eisai | Pre-clinical | 26 |
| E2007 (perampanel) + E2007 (perampanel) + Placebo | Eisai | Phase 3 | 40 |
| Perampanel + Placebo | Eisai | Phase 3 | 40 |
| E2007 (perampanel) + E2007 (perampanel) + Placebo | Eisai | Phase 3 | 40 |
| Adjunctive Zonisamide + Replacement with Zonisamide | Eisai | Approved | 43 |
| Fycompa | Eisai | Pre-clinical | 26 |
| Zonisamide + Placebo | Eisai | Phase 3 | 40 |
| Fycompa | Eisai | Pre-clinical | 26 |
| Rufinamide | Eisai | Phase 3 | 32 |
| Eslicarbazepine Acetate tablets | Eisai | Pre-clinical | 26 |
| Perampanel | Eisai | Pre-clinical | 26 |
| Perampanel | Eisai | Pre-clinical | 26 |
| Perampanel | Eisai | Approved | 43 |
| Perampanel + Perampanel | Eisai | Pre-clinical | 26 |